Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nico Gagelmann

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Blood|January 9, 2025
GSI: myeloma-cold case closed?Maximilian Merz, Nico Gagelmann
Blood Advances|February 11, 2025
PTCy unchained in matched siblings: the D is silent in GVHDNico Gagelmann, Anant Vatsayan
American Journal of Hematology|March 13, 2025
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary ReviewNico Gagelmann, Nicolaus Kröger
Seminars in Hematology|August 2, 2024
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myelomaNico Gagelmann, Maximilian Merz
Annals of Hematology|October 30, 2020
The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic reviewNico Gagelmann, Nicolaus Kröger
Current Hematologic Malignancy Reports|August 11, 2025
Allogeneic Transplant for CMMLNico Gagelmann, Nihar Desai
The Lancet. Haematology|February 1, 2023
GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?Nico Gagelmann, Jennifer Brudno
JAMA Oncology|March 28, 2020
Double Counting of Patients in Meta-analyses of Observational Studies-ReplyNico Gagelmann, Nicolaus Kröger
International Journal of Hematology|April 14, 2022
Improving allogeneic stem cell transplantation in myelofibrosisNico Gagelmann, Nicolaus Kröger
Haematologica|March 18, 2021
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?Nico Gagelmann, Nicolaus Kröger
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Blood|January 9, 2025
GSI: myeloma-cold case closed?Maximilian Merz, Nico Gagelmann
Blood Advances|February 11, 2025
PTCy unchained in matched siblings: the D is silent in GVHDNico Gagelmann, Anant Vatsayan
American Journal of Hematology|March 13, 2025
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary ReviewNico Gagelmann, Nicolaus Kröger
Seminars in Hematology|August 2, 2024
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myelomaNico Gagelmann, Maximilian Merz
Annals of Hematology|October 30, 2020
The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic reviewNico Gagelmann, Nicolaus Kröger
Current Hematologic Malignancy Reports|August 11, 2025
Allogeneic Transplant for CMMLNico Gagelmann, Nihar Desai
The Lancet. Haematology|February 1, 2023
GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?Nico Gagelmann, Jennifer Brudno
JAMA Oncology|March 28, 2020
Double Counting of Patients in Meta-analyses of Observational Studies-ReplyNico Gagelmann, Nicolaus Kröger
International Journal of Hematology|April 14, 2022
Improving allogeneic stem cell transplantation in myelofibrosisNico Gagelmann, Nicolaus Kröger
Haematologica|March 18, 2021
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?Nico Gagelmann, Nicolaus Kröger
Pageof 12